Metformin in Alzheimer’s dementia Prevention (MAP)
Alzheimer’s dementia is the most common form of late-onset dementia. Several drugs approved to treat diabetes have been proposed for Alzheimer’s dementia treatment or prevention. The Metformin in Alzheimer’s dementia Prevention (MAP) trial is a randomized controlled phase 2/3 trial comparing the effects of long-acting metformin (reduced mass Glucophage XR), which is a drug approved to treat diabetes, versus placebo in the prevention of cognitive decline. The study will measure changes over 24 months in verbal memory performance in persons with mild cognitive impairment who are at risk of developing Alzheimer’s.
Eleven sites across the U.S. are enrolling 370 persons ages 55 to 90 into this clinical trial. The trial is supported by the Trial Innovation Network and funded by the NIH National Institute on Aging. BIOS CTCC, in its role as the JHU-Tufts Trial Innovation Center, serves as the data coordinating center, site start-up manager, and central imaging center. Johns Hopkins Medicine serves as the IRB of record. Dr. Jose Luchsinger at Columbia University leads the clinical coordinating center, monitoring center, and central laboratory. The central pharmacy duties are shared by the University of Iowa and the University of Rochester.
Clinicaltrials.gov Identifier: NCT04098666